altona Diagnostics GmbH

DUBLIN--( BUSINESS WIRE )--The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Market: Forecasts by Application by Place and by Country, with Market Analysis & Executive Guides" report has been added to ResearchAndMarkets.com's offering. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. Find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. This research makes you the expert in your organization. The report includes five year market forecasts. The section on the Clinical Laboratory Market Segments and Industry Structure provides an analysis of the laboratory market, detailing traditional segmentation and focusing on specific areas like syndromic testing. It explores how different types of labs, including hospital labs, central labs, and physician office labs (POLs), segment their services based on testing needs. The industry structure section discusses the distribution of testing among hospitals, the economies of scale achieved by larger lab networks, and the competition between hospital-based labs and centralized laboratories. It also highlights the role of physician offices and the growing relevance of Point-of-Care Testing (POCT), reflecting the shifting dynamics in where and how diagnostic testing is conducted. This summary encapsulates the key market dynamics and structural elements of the clinical laboratory industry. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations. Trends like Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 2 Introduction and Market Definition 2.1 Market Definition 2.2 Methodology 2.3 Perspective: Healthcare and the IVD Industry 2.3.1 Global Healthcare Spending 2.3.2 Spending on Diagnostics 2.3.3 Important Role of Insurance for Diagnostics 2.4 The Nature of the IVD Product 2.4.1 Features Overview 2.4.2 The Misunderstood Feature 2.4.3 Regulation 2.4.4 The Newest Feature 2.4.5 The Oldest Feature 2.4.6 All About Scope 2.4.7 Why Turnaround is Becoming More Important 2.4.8 The Role of Trust 2.5 The IVD Product of the Future 3 Infectious Diseases - Guide to the Pathogens 3.1 Infectious Disease Pathogens - The Big Picture 3.1.1 Viruses 3.1.2 Bacteria 3.1.3 Fungi 3.1.4 Parasites 3.1.5 Prions 3.1.6 Virulence 3.1.7 Transmission 3.2 The Coronavirus 3.2.1 Severe acute respiratory syndrome (SARS) 3.2.2 Middle East respiratory syndrome (MERS) 3.2.3 COVID-19. The SARS CoV 2 Virus. 4 Industry Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 The Clinical Laboratory Market Segments 4.2.1 Traditional Market Segmentation 4.2.2 Laboratory Focus and Segmentation 4.2.3 Segmenting the Syndromic Testing Market 4.3 Industry Structure 4.3.1 Hospital Testing Share 4.3.2 Economies of Scale 4.3.3 Hospital vs. Central Lab 4.3.4 Physician Office Labs 4.3.5 Physicians and POCT 5 Market Trends 5.1 Factors Driving Growth 5.1.1 The Nucleic Acid Impact 5.1.2 Population Dynamics 5.1.3 The Developing World 5.1.4 Decentralization 5.1.5 Self Testing 5.1.6 The Need for Speed 5.2 Factors Limiting Growth 5.2.1 Costs and Experience Curve Effects 5.2.2 The Role of ID Prevalence 5.2.3 Wellness 5.2.4 The Impact of Living Standards 5.3 Instrumentation, Automation and Diagnostic Trends 5.3.1 Traditional Automation and Centralization 5.3.2 The New Automation, Decentralization and Point Of Care 5.3.3 Instruments Key to Market Share 5.3.4 Bioinformatics Plays a Role 5.3.5 PCR Takes Command 5.3.6 Next Generation Sequencing Fuels a Revolution 5.3.7 NGS Impact on Pricing 5.3.8 Whole Genome Sequencing, A Brave New World 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 6 Clinical Laboratory MDx Infectious Disease Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 Roche Respiratory Panel Receives FDA EUA 6.3 Genetic Signatures Gets Approval for GI Parasite Panel 6.4 Diasorin Expands Respiratory Panel 6.5 BioMerieux Outlines MDx-Driven Growth 6.6 T2 Biosystems Gets Extended T2Bacteria Panel 6.7 Diasorin Aims to Deliver Updated Instruments, New Assays 6.8 Oxford Nanopore Nabs Investment From BioMerieux 6.9 Day Zero Diagnostics Closes Financing Round 6.10 Spindiag Seeks Investors for Rapid PCR System 6.11 Sorrento Therapeutics Nabs Contract for Dx Platform 6.12 Kephera Planning Menu of Infectious Disease Tests 6.13 Oxford Nanopore and BioMerieux to Develop IDDx 6.14 SD Biosensor Eyes Global Expansion 6.15 Selux Dx Next Gen Phenotyping Gets FDA Clearance 6.16 Takara Developing High-Throughput Multiplex Panels 6.17 BioGX Debuts New Point-of-Care Molecular Testing System 6.18 Nanopath MDx Platform Providing 15-Minute Results 6.19 ProtonDx Commercializing Rapid MDx Instrument 6.20 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform 6.21 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays 6.22 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS 6.23 Accelerate Diagnostics Anticipates Growth 6.24 Growth of Decentralized Testing Expected to Continue 6.25 Lumos Diagnostics Expanding Test Portfolio 6.26 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens 6.27 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients 7 Key Companies 7.1 Abbott Laboratories 7.2 Agilent 7.3 Altona Diagnostics 7.4 Anitoa 7.5 Autonomous Medical Devices 7.6 Beckman Coulter Diagnostics (Danaher) 7.7 Becton, Dickinson and Company 7.8 BioGX 7.9 Biomatik 7.10 bioMerieux Diagnostics 7.11 Bio-Rad Laboratories, Inc 7.12 Cepheid (Danaher) 7.13 Diasorin S.p.A. 7.14 DNAe 7.15 Flow Health 7.16 Global Access Diagnostics 7.17 Great Basin Scientific, Inc 7.18 Hologic 7.19 Novacyt 7.20 Novus Diagnostics 7.21 Oncimmune 7.22 One Codex 7.23 OraSure Technologies 7.24 Proof Diagnostics 7.25 Qiagen 7.26 QuidelOrtho 7.27 R-Biopharm AG 7.28 Response Biomedical 7.29 Revvity 7.30 Roche Diagnostics 7.31 Siemens Healthineers 7.32 Thermo Fisher Scientific 7.33 Vela Diagnostics 7.34 Veredus Laboratories 7.35 YD Diagnostics 7.36 Zhejiang Orient Gene Biotech 8 The Global Market for Clinical Laboratory MDx Infectious Disease 8.1 Global Market Overview by Country 8.2 Global Market by Application - Overview 8.3 Global Market by Place - Overview 9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application 9.1 Respiratory 9.2 Blood Borne Virus 9.3 Transplant 9.4 Hospital Acquired Infections 9.5 Reproductive Health 9.6 C19 Singleplex 9.7 Meningitis 9.8 Gastrointestinal 9.9 Tropical 10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place 10.1 Hospital Lab 10.2 Outpatient Lab 10.3 Point of Care 10.4 Other Place 11 Appendices 11.1 Growth of Approved IVD Test Menu 11.2 Growth of Approved Average IVD Test Fee 11.3 The Most Used IVD Assays 11.4 The Highest Grossing Assays 11.5 Laboratory Fees Schedule For more information about this report visit https://www.researchandmarkets.com/r/fte25m About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "European Life Science Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering. The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 3.4% from 2024 through 2029. This report provides a comprehensive analysis of the European market for life science tools and reagents, including the leading companies, their revenues, product portfolios and recent activities. It looks at the competitive landscape, trends and market dynamics, such as drivers, restraints and opportunities. It also analyzes the current and future markets. The reagents studied are antibodies, enzyme-linked immunosorbent assay (ELISA) kits, protein reagents and probes. The life science tools included are hybridization systems, PCR, Western blotting instruments and ELISA instruments. The countries whose markets are analyzed are Germany, France, the U.K., Italy, Spain, Switzerland and the Rest of Europe. Markets are also analyzed by application. One of Europe's most significant strategic assets is the life science industry, which produces cutting-edge drugs and vaccines essential to the long-term health and security of European residents. Innovation in the field of life science has transformed the trajectory of a number of diseases. According to the EFPIA article on Competitiveness Strategy for European Life Science, HIV, which was once considered a deadly disease, has now been changed to a manageable disease, significant advances in cancer care have transformed survival rates, 95% of patients can now be cured of hepatitis C, and new tools have been developed to manage cardiovascular diseases and obesity. During the 1980s Europe was considered the global leader in pharmaceutical discovery, development and manufacturing. However, that position has gradually been ceded to the U.S., which is currently dominating the global healthcare industry. Of the top 50 global pharmaceutical companies, only 10 are headquartered in Europe. As the highest revenue-generating companies will invest more in R&D, U.S. companies are expected to hold a competitive edge in the near future. A recent report published in 2023, as an initiative of Biomed Alliance in Europe, EuropaBio, and Johnson & Johnson, highlights that by 2021, the public investments in healthcare research in the U.S. reached $43.6 billion (€40 billion), compared to $9.4 billion (€8.4 billion) annually in the Europe. The number of clinical trials conducted in European countries is also lower than in the U.S. In addition, as emerging markets such as China and Korea continue to expand, research activity is moving from Europe to these regions. Therefore, it is imperative for the European government to take certain measures to regain its position in the healthcare industry. Such measures include slowly increasing spending on research and ensuring research and development activities are not moving to other countries in the future. The European market for life science tools and reagents is expected to grow from $12.5 billion in 2024 to $15.3 billion by the end of 2029, at a CAGR of 4.2% from 2024 through 2029. The European market for life science COVID-19 diagnostics products is expected to decline from $479.6 million in 2024 to $29.4 million by the end of 2029, at a negative CAGR of 42.8% from 2024 through 2029. European Life Science Tools and Reagents Market Scope An analysis of the European market for life science tools and reagents, including COVID-19 diagnostics products Analyses of the market trends, with historic market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029 Estimates of the market size and revenue forecasts for the market for life science tools and reagents, with market share analysis by product, application, and country Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG scores, and consumer attitudes Competitive intelligence, including companies' market shares, recent M&A activity and venture funding Profiles of the leading companies, including Thermo Fisher Scientific Inc., Danaher Corp., Merck KGaA, Qiagen and Roche Full List of Company Profiles Included in this Report: Agilent Technologies Inc. Altona Diagnostics Gmbh Analytik Jena GmbH+Co. KG BD Bio-Rad Laboratories Inc. Danaher Corp. F. Hoffmann-La Roche Ltd. Merck KGaA Promega Corp. Qiagen Revvity Inc. Thermo Fisher Scientific Inc. Key Attributes: Report Attribute Details No. of Pages 128 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $13 Billion Forecasted Market Value (USD) by 2029 $15.4 Billion Compound Annual Growth Rate 3.4% Regions Covered Europe Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Product Development in Life Science Chapter 3 Market Dynamics Market Drivers Increasing Investments in R&D Increasing Prevalence of Chronic Diseases Increasing Demand for Various Diagnostics Pathways and In Vitro Diagnostics Growth in Genomic and Biomarker Research Increasing Demand for Personalized Medicine Technological Advances Market Restraints End of COVID-19 Pandemic High Cost of Instruments Lack of Skilled Personnel Market Challenges Regulatory Hurdles Market Opportunities Positive Impact from Some Revisions in Pharmaceutical Legislation New Technologies Chapter 4 Emerging Technologies and Developments Overview Next-Generation Therapeutics Next-Generation Diagnostics Digitalization AI and Machine Learning Internet of Things (IoT) Robots in Life Science Labs Chapter 5 Market Segmentation Analysis European Market for Life Science Tools and Diagnostics, by Product Type COVID-19 Diagnostic Tests Market Market for Life Science Tools and Reagents European Market for Life Science Tools and Diagnostics, by Application Genomics Proteomics Cell Biology, Antibodies and Recombinant Proteins Stem Cells Research Imaging Tools and Techniques Animal Models Epigenetics Metabolomics Other Applications European Market for Life Science Tools and Diagnostics, by Country United Kingdom Germany France Switzerland Spain Italy Rest of Europe Chapter 6 Competitive Intelligence PCR Technologies and Reagents Antibodies ELISA Instruments ELISA Kits and Assays Life Science Kits and Assays COVID-19 Diagnostics Strategic Initiatives Recent Product Introductions in the Market Chapter 7 Sustainability in Life Science Tools and Reagents in the European Market: An ESG Perspective Introduction to ESG ESG Practices in the Industry Status of ESG in the Industry Concluding Remarks Chapter 8 Appendix For more information about this report visit https://www.researchandmarkets.com/r/vzsyqe About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With Analysis and Executive Guides. 2023-2027" report has been added to ResearchAndMarkets.com's offering. In a Post Pandemic world molecular diagnostics sees technologies boom. Nucleic acids become key. The global market for molecular diagnostics (MDx) in infectious diseases is analyzed across various dimensions in this report. It begins with an overview of the global market by country, providing insights into regional trends and dynamics. The market is further segmented by syndrome, offering detailed analysis of key areas such as respiratory, gastrointestinal, blood, meningitis/encephalitis, sexually transmitted diseases, and others. Additionally, the report examines the market by plex, distinguishing between single plex, duplex, triplex, and multiplex technologies and their respective market landscapes. Furthermore, the analysis extends to different places where MDx testing is conducted, including hospital labs, outpatient labs, point-of-care settings, and other locations. This comprehensive examination provides valuable insights into the global MDx infectious disease markets, enabling stakeholders to make informed decisions and capitalize on emerging opportunities. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. Key Topics Covered: 1 Market Guides 1.1 Strategic Situation Analysis 1.2 Guide for Executives and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 What are Molecular Diagnostics? 2.2 The Diagnostics Revolution 2.3 Market Definition 2.3.1 Revenues 2.4 Methodology 2.4.1 Methodology 2.4.2 Sources 2.4.3 Authors 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 3 The Infectious Diseases - Market Analysis by Disease 3.1 HIV - Human Immunodeficiency Virus (AIDS) 3.1.1 Virology 3.1.1.1 Classification 3.1.1.2 Structure and Genome 3.1.1.3 Tropism 3.1.1.4 Replication cycle 3.1.1.5 Genetic variability 3.1.2 Diagnosis 3.1.3 Testing 3.1.3.1 Antibody tests 3.1.3.2 Point of Care Tests (POCT) 3.1.3.3 Antigen Tests 3.1.3.4 Nucleic acid-based tests (NAT) 3.1.3.5 Other tests used in HIV treatment 3.1.4 Market Opportunity Analysis 3.2 HBV - Hepatitis B 3.2.1 Virology 3.2.1.1 Genome 3.2.1.2 Pathogenesis 3.2.1.3 Hepatitis B virus replication 3.2.1.4 Serotypes and genotypes 3.2.2 Mechanisms 3.2.3 Diagnosis 3.2.4 Market Opportunity Analysis 3.3 HCV - Hepatitis C 3.3.1 Taxonomy 3.3.2 Structure 3.3.2.1 Genome 3.3.3 Molecular biology 3.3.4 Replication 3.3.5 Genotypes 3.3.5.1 Clinical importance 3.3.6 Market Opportunity Analysis 3.4 HPV - Human papillomavirus 3.4.1 Virology 3.4.1.1 E6/E7 proteins 3.4.1.2 Role in Cancer 3.4.1.3 E2 research 3.4.1.4 Latency period 3.4.1.5 Clearance 3.4.2 Diagnosis 3.4.2.1 Cervical testing 3.4.2.2 Oral testing 3.4.2.3 Testing men 3.4.2.4 Other testing 3.4.3 Market Opportunity Analysis 3.5 Influenza 3.5.1 Virology 3.5.1.1 Types of virus 3.5.1.2 Influenzavirus A 3.5.1.3 Influenzavirus B 3.5.1.4 Influenzavirus C 3.5.1.5 Structure, properties, and subtype nomenclature 3.5.1.6 Replication 3.5.2 Testing 3.5.2.1 Advantages/Disadvantages of Molecular Assays 3.5.3 Market Opportunity Analysis 3.6 CTGC - Chlamydia/Gonorhea 3.6.1 Gonorrhea 3.6.1.1 Diagnosis 3.6.1.2 Screening 3.6.2 Chlamydia 3.6.2.1 Diagnosis 3.6.2.2 Screening 3.6.3 Testing 3.6.3.1 Nucleic acid amplification tests (NAATs). 3.6.3.2 Performance of NAAT Tests 3.6.4 Market Opportunity Analysis 3.7 Tuberculosis 3.7.1 Mycobacteria 3.7.2 Diagnosis 3.7.2.1 Active tuberculosis 3.7.2.2 Latent tuberculosis 3.7.3 Epidemiology 3.7.4 Molecular Diagnostic Tests 3.7.5 Market Opportunity Analysis 3.8 MRSA - Methicillin-resistant Staphylococcus aureus 3.8.1 Diagnosis 3.8.2 FDA Approved Molecular Tests 3.8.3 Market Opportunity Analysis 3.9 VRE - Vancomycin-resistant Enterococcus 3.9.1 FDA-Approved MDx Tests for VRE 3.9.2 Market Opportunity Analysis 3.10 Blood Screening 3.10.1 Collection and Testing 3.10.2 FDA Approved Multiplex Assays 3.10.3 Market Opportunity Analysis 3.11 COVID-19 3.11.1 Signs and symptoms 3.11.2 Transmission 3.11.3 Diagnosis 3.11.4 Prevention 3.11.5 Management 3.11.6 Prognosis 3.12 Pandemic Diagnostics 3.12.1 Risk Management - Spark and Spread 3.12.2 Dx Technology - Nucleic Acid-Based 3.12.3 Dx Technology - Immunoassay & Serology 3.12.4 Time to Market and Preparedness Issues 3.12.5 Unrecognized Role of Multiplex in Pandemic Management 4 Industry Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 The Clinical Laboratory Market Segments 4.2.1 Traditional Market Segmentation 4.2.2 Laboratory Focus and Segmentation 4.3 Industry Structure 4.3.1 Hospital Testing Share 4.3.2 Economies of Scale 4.3.2.1 Hospital vs. Central Lab 4.3.3 Physician Office Lab's 4.3.4 Physicians and POCT 5 Profiles of Key MDx Companies 6 Market Trends 6.1 Factors Driving Growth 6.1.1 New Genotypes Creating New Markets 6.1.2 The Aging Effect 6.1.3 Developing World Driving ID Dx Growth 6.1.4 Point of Care - Why Centralization is Losing Steam 6.1.5 Self Testing 6.1.6 The Need for Speed 6.1.7 The COVID Pandemic 6.2 Factors Limiting Growth 6.2.1 Lower Costs 6.2.2 Infectious Disease is Declining 6.2.3 Wellness Hurts 6.2.4 Economic Growth Improves Living Standards 6.3 Instrumentation and Automation 6.3.1 Instruments Key to Market Share 6.3.2 The Shrinking Machine 6.3.3 Multiplex, Point of Care, and The Speed Factor 6.4 Diagnostic Technology Development 6.4.1 The Sepsis Testing Market - A New Direction? 6.4.2 POCT/Self Testing as a Disruptive Force 6.4.3 The Genetics Play - One Test for All Known Infections 6.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics 7 Molecular Dx - Infectious Disease Recent Developments 7.1 Recent Developments - Importance and How to Use This Section 7.1.1 Importance of These Developments 7.1.2 How to Use This Section Company Profiles Abacus Diagnostica Abbott Laboratories Accelerate Diagnostics Access Bio Ador Diagnostics ADT Biotech Akonni Biosystems Altona Diagnostics Alveo Technologies Anatolia Geneworks Anitoa Antelope Dx Applied BioCode Assurance Scientific Laboratories Aureum Diagnostics Aus Diagnostics Beckman Coulter Diagnostics Becton, Dickinson, and Company Binx Health Biocartis BioFire Diagnostics (bioMerieux) bioMerieux Diagnostics Bio-Rad Laboratories, Inc Bosch Healthcare Solutions GmbH Celemics Cepheid (Danaher) Chembio Co Diagnostics Credo Diagnostics Biomedical Cue Health Curetis N.V. / Curetis GmbH Detect Diagenode Diagnostics Diascopic Diasorin S.p.A. Domus Diagnostics Eiken Chemical Element Biosciences Enzo Biochem Eurofins Scientific Fluxergy Fulgent Genetics Fusion Genomics. Genedrive Genetic Signatures GenMark Dx (Roche) Genomadix Grifols Grip Molecular Technologies Hibergene Diagnostics Hologic Illumina Immunexpress Inflammatix Invetech Janssen Diagnostics Karius Lexagene LightDeck Diagnostics Lucira Health Luminex Corp (DiaSorin) LumiraDx Lumos Diagnostics Mammoth Biosciences Maxim Biomedical Meridian Bioscience Mesa Biotech (Thermo Fisher) MicroGem Millipore Sigma Mindray Minute Molecular Mobidiag (Hologic) Molbio Diagnostics NanoDx Nanomix Novacyt Novel Microdevices OnsiteGene Operon Oxford Nanopore Technologies Panagene Pathogenomix Perkin Elmer Prenetics Primerdesign (Novacyt) Prominex Proof Diagnostics Qiagen QuantuMDx Quest Diagnostics QuidelOrtho Randox Toxicology Roche Molecular Diagnostics Saw Diagnostics Scope Fluidics SD Biosensor Seegene Siemens Healthineers Singular Genomics SomaLogic Sona Nanotech SpeeDx T2 Biosystems Talis Biomedical Thermo Fisher Scientific Inc. Ultima Genomics Vela Diagnostics Veramarx Veredus Laboratories Vir Vircell Visby Medical XCR Diagnostics YD Diagnostics Zhejiang Orient Gene Biotech For more information about this report visit https://www.researchandmarkets.com/r/twbxfg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.